Lv2
138 积分 2022-10-24 加入
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
1个月前
已完结
Survodutide Once Weekly for the Treatment of Adults with Obesity
1个月前
已完结
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
1个月前
已完结
Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
1个月前
已完结
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
1个月前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
1个月前
已完结
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
1个月前
已完结
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
1个月前
已完结
Tirzepatide for Obesity Treatment and Diabetes Prevention
1个月前
已完结
A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity
1个月前
已完结
皖公网安备34019202002308
